Health-related quality of life in inflammatory bowel disease

PharmacoEconomics

Volumn 10, Issue 4, 1996, Pages 327-335

  Eisen, Glenn M ^a   Farmer, Richard G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENTERITIS; HEALTH CARE COST; HEALTH STATUS; HUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW;

EID: 0029788558     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199610040-00003     Document Type: Review

References (46)

1. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's disease activity index (CDAI). Gastroenlerology 1979; 77: 843-6
2. Harvey RF, Bradshaw JM. A simple index of Crohn's disease activity. Lancet 1980; 1: 514-5
3. Truelove SC, Witts IJ, Cortisone in ulcerative colitis: preliminary report in a therapeutic trial. BMJ 1954; 2: 374-8
4. Hodgson HJF, Mazlam MZ. Review article: assessment of drug therapy in inflammatory bowel disease. Aliment Pharmacol Ther 1991; 5: 555-84
5. Calkins BM, Mendeloff AI. Epidemiology of inflammatory bowel disease. Epidemiol Rev 1986; 8: 60-91
6. Sandler RS, Golden AL. Epidemiology of Crohn's disease. J Clin Gastroenterol 1986; 8: 160-8
7. Farmer RG, Hawk WA, Turnbull RB. Clinical patterns in Crohn's disease: a statistical study of 615 patients. Gastroenterology 1975; 68: 627-35
8. Shumaker SA, Anderson RT, Czajkowski SM. Psychological lest and scales. In: Spilker B, editor. Quality of life assessment in clinical trials. New York. Raven Press, 1990: 95-114
9. Kirshner B, Guyatt GH. A methodological framework for assessing health indices. J Chronic Dis 1988; 38: 27-36
10. Barofsky I, Sugarbaker PH. Cancer. In: Spilker B, editor. Quality of life assessment in clinical trials. New York: Raven Press, 1990: 419-40
11. Stewart AI, Greenfield S, Hays RD, et al. Functional status and well-being of patients with chronic conditions: results from the Medical Outcomes Study. JAMA 1989; 262: 907-13
12. Bergner M, Bobbitt RA, Pollard M, et al. The sickness impact profile: validation of a health status measure. Med Care 1976; 14: 57-67
13. Singleton JW, Hanauer S, Robinson M. Quality of life results of a double blind, placebo controlled trial of mesalamine in patients with Crohn's disease. Dig Dis Sci 1995; 40: 931-5
14. Guyatt G, Mitchell A, Irvine EJ, et al. A new measure of health status for clinical trials in IBD. Gastroenterology 1989; 96: 804-10
15. Love JR, Irvine EJ, Fedorak RN. Quality of life in inflammatory bowel disease. J Clin Gastroenterol 1992; 14: 15-9
16. Farmer RG, Easley KA, Farmer JM. Quality of life assessment by patients with inflammatory bowel disease. Cleve Clin J Med 1992; 59: 35-42
17. Drossman DA, Leserman J, Li Z, et al. The rating form of IBD patient concerns: a new measure of health status. Psychosom Med 1991; 53: 701-12
18. Drossman DA, Li Z, Leserman J, et al. Ulceralive Colitis and Crohn's Disease Health Status scales for research and clinical practice. J Clin Gastroenterol 1992; 15: 104-12
19. McLeod RS, Cohen Z, Churchill DN, et al. Measurement of quality of life of patients with ulcerative colitis undergoing surgery. Gastroenterology 1991; 101: 1307-13
20. Welch G, Richter J, Kawachi I, et al. The SF-36 quality of life measure in inflammatory bowel disease: an evaluation of its reliability and validity [abstract]. Gastroenterology 1995; 108: A940
21. Drossman DA, Patrick DL, Mitchell CM, et al. Health-related quality of life in inflammatory bowel disease: functional status and patient worries and concerns. Dig Dis Sci 1989; 34: 1379-86
22. Drossman DA, Leserman J, Mitchell CM, et al. Health status and health care use in persons with inflammatory bowel disease: a national sample. Dig Dis Sci 1991; 36: 1746-55
23. Folkman S, Lazarus RS, Gruen RJ, et al. Appraisal, coping, health status, and psychological symptoms. J Pers Soc Psychol 1986; 50: 571-9
24. Mitchell AM, Guyatt G, Singer J, et al. Quality of life in patients with inflammatory bowel disease. J Clin Gastroenterol 1988; 10: 306-10
25. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287-96
26. Van Hees PAM, van Elteren PH, van Lier JJ, et al. An index of inflammatory activity in patients with Crohn's disease. Gut 1980; 21: 279-84
27. Powell-Tuck J, Day DW, Bucknell NA, et al. Correlations between defined sigmoidoscopic appearances and other measures of disease activity in ulcerative colitis. Dig Dis Sci 1982; 27: 533-7
28. Feagan BG, McDonald JWD, Rochon J, et al. Low dose cyclosporine for the treatment of Crohn's disease. N Engl J Med 1994; 330: 1846-51
29. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. N Engl J Med 1994; 331: 836-41
30. Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. N Engl J Med 1995; 332: 292-7
31. Irvine EJ, Zhou Q, Thompson AK and the CCRPT investigators. The short inflammatory bowel disease questionnaire: a quality of life instrument for community physicians managing inflammatory bowel disease. Am J Gastroenterol 1996; 91 (8): 1571-8
32. Jaesehke R, Guyatt GH, Cook D. Quality of life instruments in the evaluation of new drugs. Pharmacoeconomics 1992; 1: 84-94
33. Derogatis LR. SCL-90-R: administration, scoring and procedures manual 11-for the revised version. Towson: Clinical Psychometric Research, 1983
34. Talal AH, Drossman DA. Psychosocial factors in inflammatory bowel disease. Gastroenterol Clin North Am 1995; 24 (3): 699-716
35. Drossman DA. Inflammatory bowel disease. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. New York: Lippincolt Raven Press, 1996: 925-36
36. Morowitz DA, Kirsner JB. Ileostomy in ulcerative colitis: a questionnaire study of 1,083 patients. Am J Surg 1981; 141: 370-5
37. Roy PH, Sauer WG, Beahrs OH, et al. Experience with ileostomies: evaluation of long-term rehabilitation in 447 patients. Am J Surg 1970; 119: 77-86
38. McLeod RS. Quality of life assessment in gastrointestinal surgery. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. New York: Lippincott Raven Press, 1996
39. Torrance GW, Thomas WH, Sackett DL. A utility maximization model for the evaluation of health care programs. Health Serv Res 1972; 7: 118-33
40. Farmer RG. Human cost of inflammatory bowel disease. Can J Gastroenterol 1994; 8: 140-4
41. Brown DM, Everhart JE. Cost of digestive diseases in the United States. In: Everhart JE, editor. Digestive diseases in the United States: epidemiology and impact. U.S. Department of Health and Human Services, Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Washington D.C.: US Government Printing Office, 1994; NIH publication no. 94-1447: 57-81
42. Hay JW, Hay AR. Inflammatory bowel disease: costs of illness. J Clin Gastroenterol 1992; 14: 309-17
43. Wennberg JE. Outcomes research, cost containment and the fear of health care rationing. N Engl J Med 1990; 323: 1202-4
44. Guyatt GH, Feeny DH, Patrick DL. Measuring health related quality of life. Ann Intern Med 1993; 118: 622-9
45. Feeny D, Labelle R, Torrance GW. Integrating economic evaluations and quality of life assessments. In: Spilker B, editor. Quality of life assessments in clinical trials. New York: Raven Press, 1990: 71-83
46. Drummond MF, Stoddart GL, Torrance GW. Methods for economic evaluation of health care programmes. Oxford: Oxford University Press, 1987